- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01465360
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
Performance of AclarusDx™, A Blood-Based Transcriptomic Test for Alzheimer's Disease, in US-based Patients Suffering From Memory Impairment and Newly Referred to A Reference Memory Center, for AD Diagnostic Workup-A Pilot Descriptive Study
Studieoversigt
Status
Detaljeret beskrivelse
The objective of this study is to apply AclarusDx™ signature in a reference US Center in 160 patients newly referred to one of the three study centers within the Cleveland Clinic, Center for Brain Health network, for diagnostic workup. Only AclarusDx™ will be added to the panel of tests usually performed at the centers to establish diagnosis. AclarusDx™ will be used for investigational use only, not for diagnostic purpose. The ultimate goal is to define the clinical utility of AclarusDx™ to provide Primary Care Physicians (PCPs) with a tool that will help them in making the diagnosis of Alzheimer's Disease (AD).
The primary objectives are :
- To obtain an estimate of the capability of AclarusDx™ to identify AD patients among a US-based population of newly referred patients suffering from objective memory impairment which maybe potentially related to multiple and different etiologies.
- To compare the performance of AclarusDx™ in a US-based population of newly referred patients with memory impairment with the performance of AclarusDx™ observed in one comparable European population.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89106
- Cleveland Clinic Lou Ruvo Center for Brain Health
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Center for Brain Health - Mellen Center
-
Lakewood, Ohio, Forenede Stater, 44107
- Cleveland Clinic Senior Care Assessment - Lakewood Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Male or female patient referred to the center for memory impairment.
- The memory impairment has previously been observed by a caregiver or documented by a physician.
- The memory impairment is confirmed by the memory center.
- Caucasian ethnicity.
- A written informed consent approved by an ethical review board or similar body must be obtained from the patient prior to any study-related procedures.
- If applicable, standard treatment with cholinesterase inhibitor and/or memantine is acceptable.
- Patient estimated to be compliant with study procedures.
- Patient has a level of understanding sufficient to agree to all procedures required by the protocol and must be able to cooperate. Under no circumstances will a subject who does not understand the procedure, be allowed to consent to the procedure.
Exclusion Criteria:
- Recent acute pathology or medical condition or surgery which may alter the inflammatory homeostasis, according to the opinion of the investigator.
- Non-Caucasian ethnicity.
- Patient with severe uncontrolled or unstable medical condition.
- Need for a legal representative for the medical condition of the patient.
- Any current pathology or medical condition, for which blood sampling may involve a risk for the patient's health, according to the opinion of the investigator.
- Current or recent history (within one month) of clinically significant pathology, medical condition (including hospitalization) or symptoms. However, chronic diseases or medical conditions that are considered stable are accepted, provided that they are compatible with other study selection criteria.
- Current or recent history of drug or alcohol abuse or dependence.
- Current, clinically significant major psychiatric disorder (eg, major depressive disorder) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition text revised (DSM-IV TR), or significant symptoms (eg, hallucinations).
- Woman of childbearing potential is not allowed to participate in the study. (A woman of childbearing potential is a woman who is biologically capable of becoming pregnant).
- Current participation in another study using an investigational non-marketed product.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Study patients
Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensitivity of AclarusDx™ in AD patients
Tidsramme: Outcome measured during one single study visit
|
The determination of the sensitivity of the test, being the percentage of positive AclarusDx™ calls among referred patients being confirmed clinically as having AD at the Memory Center will be calculated.
|
Outcome measured during one single study visit
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Charles B. Bernick, MD, Cleveland Clinic Lou Ruvo Center for Brain Health
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Hjerte-kar-sygdomme
- Karsygdomme
- Metaboliske sygdomme
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Åreforkalkning
- Arterielle okklusive sygdomme
- Neurologiske manifestationer
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Parkinsonlidelser
- Basal Ganglia Sygdomme
- Bevægelsesforstyrrelser
- Synukleinopatier
- Neurodegenerative sygdomme
- TDP-43 Proteinopatier
- Proteostase mangler
- Tauopatier
- Kognitionsforstyrrelser
- Sprogforstyrrelser
- Kommunikationsforstyrrelser
- Intrakranielle arterielle sygdomme
- Taleforstyrrelser
- Frontotemporal Lobar Degeneration
- Intrakraniel arteriosklerose
- Leukoencefalopati
- Parkinsons sygdom
- Demens
- Alzheimers sygdom
- Kognitiv dysfunktion
- Afasi
- Frontotemporal demens
- Afasi, Primær Progressiv
- Pick sygdom i hjernen
- Demens, Vaskulær
Andre undersøgelses-id-numre
- EHTAD/003
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mild kognitiv svækkelse
-
Uskudar UniversityRekrutteringAMCI - Amnestic Mild Cognitive ImpairmentTyrkiet (Türkiye)
-
IRCCS San RaffaeleAktiv, ikke rekrutterendeMild kognitiv svækkelse (MCI) | Neurodegenerativ sygdom | Neurodegenerativ demens | AMCI - Amnestic Mild Cognitive ImpairmentItalien
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RekrutteringSøvnforstyrrelser | AMCI - Amnestic Mild Cognitive ImpairmentForenede Stater
-
IRCCS San RaffaeleRekrutteringAlzheimers sygdom | MCI | AMCI - Amnestic Mild Cognitive Impairment | MCI Konvertering til demensItalien
-
Charité Neurocure AG FlöelUkendtAfasi | Anomi (ord-finding impairment)Tyskland
-
Dart NeuroScience, LLCAfsluttetAge-Associated Memory Impairment (AAMI)Forenede Stater
-
State University of New York at BuffaloAfsluttet
-
Ludwig-Maximilians - University of MunichBayerisches Staatsministerium für Gesundheit, Pflege und PräventionRekrutteringMild kognitiv svækkelse | Mild demensTyskland
-
NYU Langone HealthRekruttering
-
Dr. Grace ParragaCyclomedica Australia PTY LimitedIkke rekrutterer endnu